{"protocolSection":{"identificationModule":{"nctId":"NCT04608838","orgStudyIdInfo":{"id":"JTR-161-201"},"organization":{"fullName":"Teijin Pharma Limited","class":"INDUSTRY"},"briefTitle":"A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)","officialTitle":"An Exploratory, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety and Efficacy of JTR-161 in Patients With Acute Ischemic Stroke","acronym":"J-REPAIR"},"statusModule":{"statusVerifiedDate":"2022-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-01-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-02-15","type":"ACTUAL"},"completionDateStruct":{"date":"2021-11-24","type":"ACTUAL"},"studyFirstSubmitDate":"2020-09-08","studyFirstSubmitQcDate":"2020-10-28","studyFirstPostDateStruct":{"date":"2020-10-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-06-28","lastUpdatePostDateStruct":{"date":"2022-06-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Teijin Pharma Limited","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The objective of this study is to evaluate the safety and efficacy of a single intravenous administration of JTR-161 (allogeneic stem cell product derived from the dental pulp of healthy adult humans) to patients with acute ischemic stroke.\n\nThis study is comprised of 3 cohorts and conducted in the order of Cohort 1, Cohort 2 and Cohort 3.\n\nCohort 1 Arm-1: JTR-161, 1 × 10\\^8 cells/subject, 6 subjects Arm-2: Placebo, 2 subjects\n\nThe Data and Safety Monitoring Board (DSMB) and the Sponsor will decide whether Cohort 2 can be initiated or not.\n\nCohort 2 Arm-1: JTR-161, 3 × 10\\^8 cells/subject, 6 subjects Arm-2: Placebo, 2 subjects\n\nDSMB and the Sponsor will decide whether Cohort 3 can be initiated or not and the dose of JTR-161 in Cohort 3.\n\nCohort 3 Arm-1: JTR-161, 1 × 10\\^8 cells/subject or 3 × 10\\^8 cells/subject, 30 subjects Arm-2: Placebo, 30 subjects"},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"Some care providers who involved in the preparation or administration of dosing solutions are unblinded.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":79,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"JTR-161","type":"EXPERIMENTAL","interventionNames":["Biological: JTR-161"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"JTR-161","description":"JTR-161 (1 or 3 × 10\\^8 cells/subject) will be suspended and administered in an intravenously infusion.","armGroupLabels":["JTR-161"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Placebo will be suspended and administered in an intravenously infusion.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The percentage of patients who achieved Excellent outcome (modified Rankin Scale [mRS] ≤1 and National Institutes of Health Stroke Scale [NIHSS] ≤1 and Barthel Index [BI] ≥95) on Day 91 in Cohort 3.","timeFrame":"91 days"}],"secondaryOutcomes":[{"measure":"Percentage of patients who achieved mRS ≤ 1 or mRS ≤ 2","timeFrame":"366 days"},{"measure":"Percentage of patients who achieved BI ≥ 95","timeFrame":"366 days"},{"measure":"Percentage of patients who achieved NIHSS ≤ 1, who achieved improvement of ≥ 75%, and who achieved improvement of ≥ 10 points","timeFrame":"91 days"},{"measure":"Changes in EQ-5D-5L scores","description":"The EuroQOL 5 dimension 5-level (EQ-5D-5L) consists of 2 parts: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).\n\nThe descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=\"no problems\", 2=\"slight problems\", 3=\"moderate problems\", 4=\"severe problems\" and 5=\"extreme problems\".\n\nThe EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.","timeFrame":"366 days"},{"measure":"Percentage of patients who achieved excellent outcome (mRS ≤ 1, NIHSS ≤ 1, and BI ≥ 95)","timeFrame":"91 days"},{"measure":"Percentage of patients who showed overall improvement (mRS ≤ 2, NIHSS improvement of ≥ 75%, and BI ≥ 95)","timeFrame":"91 days"},{"measure":"Incidence of Adverse events (signs and symptoms)","timeFrame":"366 days"},{"measure":"Changes in Laboratory tests (hematology, blood chemistry, blood coagulation test, urinalysis)","description":"Number of participants with clinical laboratory abnormalities for each parameter\n\n* hematology Red blood cell count, Hemoglobin, Hematocrit, Platelet count, Leukocyte count, Leukocyte formula (neutrophils, lymphocytes, monocytes, eosinophils, basophils)\n* blood chemistry Total protein, Albumin, Total bilirubin, Aspartate aminotransferase , Alanine aminotransferase, Alkaline phosphatase , Lactate dehydrogenase , γ-Glutamyltransferase, Blood urea nitrogen , Creatinine, Uric acid, Sodium, Potassium, Calcium, Chloride, Creatine kinase , C-reactive protein\n* blood coagulation Prothrombin time (International normalized ratio) , Activated partial thromboplastin time\n* urinalysis Urine Protein, Urine Glucose","timeFrame":"366 days"},{"measure":"Changes in Vital signs (blood pressure [systolic/diastolic], pulse rate, body temperature)","description":"Number of participants of the vital signs abnormalities for each parameter: blood pressure (mmHg), pulse rate (bpm) and body temperature (℃).","timeFrame":"366 days"},{"measure":"Changes in Oxygen saturation (SpO2)","timeFrame":"366 days"},{"measure":"Changes in findings of imaging examination by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT).","timeFrame":"31 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who have ischemic strokes in the anterior circulation\n* Patients whose mRS is 0 or 1 prior to the onset of ischemic stroke\n* Patients whose NIHSS score of ≥5 to ≤20 at screening\n* Patients who can be administered dosing solutions within 48 h of stroke onset\n\nExclusion Criteria:\n\n* Patients who have new ischemic lesion in the cerebellum or brainstem\n* Patients whose consciousness level drops severely\n* Patients whose infarct area is widespread\n* Patients who have a clinically significant hemorrhagic transformation\n* Patients who had seizures after onset of ischemic stroke\n* Patients who have medical history of a neurological event such as stroke or clinically significant head trauma within 180 days prior to giving informed consent\n* Patients who have poor blood pressure control\n* Patients who have poor glycaemic control\n* Patients who have one of the following complications\n\n  1. Severe liver dysfunction\n  2. Severe kidney dysfunction\n  3. Severe heart failure\n  4. Severe pulmonary dysfunction\n* Patients who have severe infections\n* Patients who have any neurological disorder affecting informed consent or study assessments\n* Patients who have the malignant tumor, or medical history of malignant tumor within 2 years prior to the onset of ischemic stroke\n* Patients who have a contraindication for MRI\n* Patients who have thrombocytopenia\n* Patients who have medical history of allergy to products derived from human tissues, bovine or porcine\n* Patients who have medical history of allergy to streptomycin\n* Patients who have undergone splenectomy in the past\n* Patients who have a possibility of transient ischemic attack\n* Patients who are scheduled to undergo revascularization (carotid endarterectomy, stent placement etc.)","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Nippon Medical School Hospital","city":"Bunkyo-ku","state":"Tokyo","zip":"113-8602","country":"Japan","geoPoint":{"lat":35.37517,"lon":139.92991}}]},"referencesModule":{"references":[{"pmid":"35613802","type":"DERIVED","citation":"Suda S, Nito C, Ihara M, Iguchi Y, Urabe T, Matsumaru Y, Sakai N, Kimura K; J- REPAIR trial group. Randomised placebo-controlled multicentre trial to evaluate the efficacy and safety of JTR-161, allogeneic human dental pulp stem cells, in patients with Acute Ischaemic stRoke (J-REPAIR). BMJ Open. 2022 May 24;12(5):e054269. doi: 10.1136/bmjopen-2021-054269."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}